Point Br and Management
Total Consideration
$6.4M
Purchase-Price Allocation
Intangibles
$4.0M
Contingent Earn-Out
$800.0K
SUPERIOR GROUP OF COMPANIES, INC. — Key Metrics
3 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
M-Score (Beneish; >-1.78 flags risk)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$0
Book Value Per Share
$13
Free Cash Flow Per Share
$1
Cash Per Share
$2
Revenue Per Share
$37
OCF Per Share
$1
Return on Equity
3.6%
Return on Assets
1.7%
Debt to Equity
0.45
Current Ratio
2.66
Quick Ratio
1.76
Asset Turnover
1.35
Days Sales Outstanding
67.26
Days Payables Outstanding
49.94
Days Inventory On Hand
100.70
Cash Conversion Cycle
118.02
SBC / Revenue
0.9%
Capex / Revenue
0.7%
Working Capital
$180M
Net Current Asset Value
$59M
Invested Capital
$280M
OCF / Net Income
2.82
FCF / Net Income
2.25
Accruals Ratio (Sloan)
-3.0%
Net Debt
$63M
Net Debt / EBITDA
5.13
Cash Coverage
3.83
Dividend Coverage
2.21
Capex Coverage
4.99
Tangible Common Equity
$143M
TCE / Total Assets
33.9%
Goodwill / Total Assets
0.6%
Cash ROIC
5.6%
WC / Revenue
31.7%
Capex / D&A
0.32
Total Payout Ratio
272.0%
Asset Growth vs Revenue Growth
1.5%
Revenue 5Y CAGR
1.5%
EPS 5Y CAGR
-29.8%
FCF 5Y CAGR
-11.8%
EBITDA 5Y CAGR
8.7%
Book Value 5Y CAGR
0.1%
Stock Price (FY-end)
$10
Market Cap
$146M
P/E Ratio
20.90
P/S Ratio
0.26
P/B Ratio
0.76
P/TB Ratio
1.02
P/OCF Ratio
7.42
P/FCF Ratio
9.28
Enterprise Value
$210M
EV / EBITDA
16.98
EV / Sales
0.37
EV / FCF
13.31
FCF Yield
10.8%
Dividend Yield
6.1%
Shareholder Yield
9.4%
Buyback Yield
6.9%
Capex Yield
2.7%
Dividend Per Share
$1
DPS YoY Growth
3.3%
Graham Number
$11
Shares Variation (YoY)
-7.2%
Beta (5Y)
0.94
Cost of Equity
9.2%
Cost of Debt (after tax)
5.0%
WACC
7.6%
52W High
$16
52W Low
$8
Trailing Return 1Y
-36.3%
Trailing Return 5Y
-51.6%
F-Score (Piotroski)
4.00
M-Score (Beneish)
-2.57
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Beat / Miss vs Estimate
Stock Price on Earnings Dates
SUPERIOR GROUP OF COMPANIES, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 1.30% | 1.40% | 3.40% | 2.50% | 4.50% | 2.60% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | 0.30% | -0.30% | -0.70% | 0.50% | 1.40% | — |
| SBC (Nondeductible) | 2.30% | -1.60% | -0.80% | 2.10% | 1.90% | 7.20% |
| Valuation Allowance Change | — | — | — | — | — | 0.20% |
| Tax Law Change | — | — | — | — | — | — |
| Effective Tax Rate | 20.30% | 11.10% | 15.90% | 10.20% | 16.00% | 15.10% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $10.4M | $3.7M | −$6.1M | $997.0K | $2.3M | $1.2M |
| Income Taxes Paid (Cash) | — | — | — | — | $2.3M | $1.6M |
SUPERIOR GROUP OF COMPANIES, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.